Format

Send to

Choose Destination
Inflamm Res. 2019 Feb;68(2):167-176. doi: 10.1007/s00011-018-1198-8. Epub 2018 Nov 14.

Empowering the immune fate of bone marrow mesenchymal stromal cells: gene and protein changes.

Author information

1
Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Department of Medicine, University of Montreal, 900 Saint-Denis, R11.424, Montreal, QC, H2X 0A9, Canada. mnajar@ulb.ac.be.
2
Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Department of Medicine, University of Montreal, 900 Saint-Denis, R11.424, Montreal, QC, H2X 0A9, Canada.
3
Laboratory of Physiology, Ethnopharmacology and Genetics, Faculty of Sciences, University Mohammed Premier, Oujda, Morocco.
4
Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
5
Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Department of Medicine, University of Montreal, 900 Saint-Denis, R11.424, Montreal, QC, H2X 0A9, Canada. h.fahmi@umontreal.ca.

Abstract

OBJECTIVE AND DESIGN:

Bone marrow mesenchymal stromal cells (BM-MSCs) are referred as a promising immunotherapeutic cell product. New approaches using empowered MSCs should be developed as for the treatment or prevention of different immunological diseases. Such preconditioning by new licensing stimuli will empower the immune fate of BM-MSCs and, therefore, promote a better and more efficient biological. Here, our main goal was to establish the immunological profile of BM-MSCs following inflammatory priming and in particular their capacity to adjust their immune-related proteome and transcriptome.

MATERIAL AND METHODS:

To run this study, we have used BM-MSC cell cultures, a pro-inflammatory cytokine cocktail priming, flow cytometry analysis, qPCR and ELISA techniques.

RESULTS:

Different expression levels of several immunological mediators such as COX-1, COX-2, LIF, HGF, Gal-1, HO-1, IL-11, IL-8, IL-6 and TGF-β were constitutively observed in BM-MSCs. Inflammation priming substantially but differentially modulated the gene and protein expression profiles of these mediators. Thus, expressions of COX-2, LIF, HGF, IL-11, IL-8 and IL-6 were highly increased/induced and those of COX-1, Gal-1, and TGF-β were reduced.

CONCLUSIONS:

Collectively, we demonstrated that BM-MSCs are endowed with a specific and modular regulatory machinery which is potentially involved in immunomodulation. Moreover, BM-MSCs are highly sensitive to inflammation and respond to such signal by properly adjusting their gene and protein expression of regulatory factors. Using such preconditioning may empower the immune fate of MSCs and, therefore, enhance their value for cell-based immunotherapy.

KEYWORDS:

Bone marrow; Immunomodulation; Inflammation priming; Mesenchymal stromal cells; Regulatory mediators

PMID:
30426152
DOI:
10.1007/s00011-018-1198-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center